Skip to main content
. 2022 Sep 1;17:2043–2052. doi: 10.2147/COPD.S367701

Table 1.

Baseline Characteristics of the ITT Population

Characteristics FF/UMEC/VI (N=911) BUD/FOR (N=899) Total (N=1810)
Age, years, mean (SD) 64.2 (8.6) 63.7 (8.7) 63.9 (8.6)
Female, n (%) 233 (26) 236 (26) 469 (26)
BMI, kg/m2, mean (SD)a,b 26.9 (5.2) 27.0 (5.1) 26.9 (5.1)
Current smokers, n (%)b 400 (44) 394 (44) 794 (44)
Smoking history, pack-years, mean (SD) 39.5 (21.9) 39.2 (22.2) 39.4 (22.0)
Moderate/severe exacerbations in past year, n (%)
0 313 (34) 317 (35) 630 (35)
1 252 (28) 253 (28) 505 (28)
≥2 346 (38) 329 (37) 675 (37)
Severe exacerbations in past year, n (%)
0 726 (80) 699 (78) 1425 (79)
1 167 (18) 177 (20) 344 (19)
≥2 18 (2) 23 (3) 41 (2)
Post-bronchodilator FEV1, % predicted, mean (SD)a 45.5 (13.0) 45.1 (13.6) 45.3 (13.3)
SGRQ total score, mean (SD)c 51.8 (16.3) 50.8 (16.7) N/A
Eosinophils, 109/L, mean (SD)b,d 0.213 (0.191) 0.213 (0.280) N/A

Notes: aFF/UMEC/VI n=908, BUD/FOR n=897, total n=1805. bAt screening. cFF/UMEC/VI n=904, BUD/FOR n=893. dFF/UMEC/VI n=887, BUD/FOR n=873, total n=1804.

Abbreviations: BUD, budesonide; FEV1, forced expiratory volume in 1 second; FF, fluticasone furoate; FOR, formoterol; N/A, not available; SD, standard deviation; SGRQ, St George’s respiratory questionnaire; UMEC, umeclidinium; VI, vilanterol.